Skip to main content
. 2020 Mar 18;9(10):3390–3399. doi: 10.1002/cam4.2998

Figure 2.

Figure 2

A, Event Free Survival of CLL patients who started therapy with ibrutinib at ≥2.5 mg/kg daily dose compared to <2.5 mg/kg daily dose. B, Overall Survival of CLL patients who started therapy with ibrutinib at ≥2.5 mg/kg daily dose compared to <2.5 mg/kg daily dose